Document Detail

Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature.
MedLine Citation:
PMID:  22334452     Owner:  NLM     Status:  MEDLINE    
Interferon is the only accepted adjuvant treatment for patients with melanoma; hence, oncologists should be aware of the possibility of retinal abnormalities resulting from its use. Interferon-associated retinopathy in patients being treated for resected melanoma is a rare phenomenon with a proposed immunological basis. Patients are usually asymptomatic or have mild visual impairments, with cotton wool infarcts and hemorrhages. These symptoms and signs usually resolve with the discontinuation of interferon, but in a few severe presentations the visual impairments and retinal changes can be irreversible.
Jose G Monzon; Nazik Hammad; Samuel D Stevens; Janet Dancey
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2012-02-14
Journal Detail:
Title:  The oncologist     Volume:  17     ISSN:  1549-490X     ISO Abbreviation:  Oncologist     Publication Date:  2012  
Date Detail:
Created Date:  2012-04-02     Completed Date:  2012-09-24     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  384-7     Citation Subset:  IM    
NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Interferon-alpha / adverse effects*,  therapeutic use
Melanoma / drug therapy*,  surgery
Paraneoplastic Syndromes, Ocular / diagnosis,  pathology,  therapy*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromb...
Next Document:  Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of ...